Search Contact
NEWS
The AB-Biotics Personalized Medicine Platform (NEUROFARMAGEN) Increases Psychiatric Treatment Efficacy by 67%
17 October 2018

As part of the European College of Neuropsychopharmacology (ECNP), the biotechnology company AB-Biotics presented a study showing that patients with major depressive disorder following therapies based on pharmacogenetics improve their response to medication.